XORTX Therapeutics Net Worth
XORTX Therapeutics Net Worth Breakdown | XRTX |
XORTX Therapeutics Net Worth Analysis
XORTX Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including XORTX Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of XORTX Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform XORTX Therapeutics' net worth analysis. One common approach is to calculate XORTX Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares XORTX Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing XORTX Therapeutics' net worth. This approach calculates the present value of XORTX Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of XORTX Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate XORTX Therapeutics' net worth. This involves comparing XORTX Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into XORTX Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if XORTX Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding XORTX Therapeutics' net worth research are outlined below:
| XORTX Therapeutics generated a negative expected return over the last 90 days | |
| XORTX Therapeutics has high historical volatility and very poor performance | |
| XORTX Therapeutics has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (2.16 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| XORTX Therapeutics currently holds about 13.42 M in cash with (6.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.03, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from gurufocus.com: XORTX Commences Gout Program NDA Discussions with the FDA |
XORTX Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in XORTX Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to XORTX Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know XORTX Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as XORTX Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading XORTX Therapeutics backward and forwards among themselves. XORTX Therapeutics' institutional investor refers to the entity that pools money to purchase XORTX Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Armistice Capital, Llc | 2024-12-31 | 265 K | Ubs Group Ag | 2024-12-31 | 17.4 K | Royal Bank Of Canada | 2024-12-31 | 1.5 K | Advisor Group Holdings, Inc. | 2024-12-31 | 1.2 K | Hartland & Co | 2024-12-31 | 277 | Tower Research Capital Llc | 2024-12-31 | 0.0 | Jpmorgan Chase & Co | 2024-12-31 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 |
Follow XORTX Therapeutics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.34 M.Market Cap |
|
Project XORTX Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.49) | (0.51) | |
| Return On Capital Employed | (1.07) | (1.01) | |
| Return On Assets | (0.47) | (0.49) | |
| Return On Equity | (0.55) | (0.58) |
When accessing XORTX Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures XORTX Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of XORTX Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in XORTX Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of XORTX Therapeutics. Check XORTX Therapeutics' Beneish M Score to see the likelihood of XORTX Therapeutics' management manipulating its earnings.
Evaluate XORTX Therapeutics' management efficiency
XORTX Therapeutics has return on total asset (ROA) of (0.3314) % which means that it has lost $0.3314 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2936) %, meaning that it created substantial loss on money invested by shareholders. XORTX Therapeutics' management efficiency ratios could be used to measure how well XORTX Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.51 in 2025. Return On Capital Employed is likely to rise to -1.01 in 2025. At this time, XORTX Therapeutics' Non Current Assets Total are fairly stable compared to the past year. Intangible Assets is likely to rise to about 189 K in 2025, whereas Total Assets are likely to drop slightly above 5 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.11 | 1.59 | |
| Tangible Book Value Per Share | 2.03 | 1.22 | |
| Enterprise Value Over EBITDA | (0.16) | (0.17) | |
| Price Book Value Ratio | 0.84 | 0.88 | |
| Enterprise Value Multiple | (0.16) | (0.17) | |
| Price Fair Value | 0.84 | 0.88 | |
| Enterprise Value | 806.9 K | 910.6 K |
Understanding the operational decisions made by XORTX Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
XORTX Therapeutics time-series forecasting models is one of many XORTX Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary XORTX Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.XORTX Therapeutics Earnings per Share Projection vs Actual
XORTX Therapeutics Corporate Management
| MD MBA | Chief Officer | Profile | |
| MBA DVM | Chief Officer | Profile | |
| Charlotte May | Corporate Secretary | Profile | |
| MRCP MD | Chief Officer | Profile | |
| David MacDonald | Consultant Operations | Profile | |
| Nick Rigopoulos | Director Communications | Profile |
Already Invested in XORTX Therapeutics?
The danger of trading XORTX Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of XORTX Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than XORTX Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile XORTX Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for XORTX Stock Analysis
When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.